BioCentury
ARTICLE | Strategy

CHMX blames poor Actinex sales on ignorance

November 8, 1993 8:00 AM UTC

Chemex Pharmaceuticals Inc., which reported disappointing Actinex sales, said the problem may be due to lack of patient awareness that there is a less-invasive treatment for actinic keratoses (premalignant skin lesions).

CHMX had hoped for double the $25,000 received in Actinex royalties in the third quarter from marketing partner Block Drug. CHMX receives 2.5 percent on gross sales until total cumulative revenues exceed $40 million, when the royalty will rise to 5 percent. The product received U.S. marketing approval last year...